To investigate this further, and determine whether elimination of Tregs using PC61 could adversely affect T cell dependent immunotherapy of GBM, we implanted tumors in the striatum on day 0 and mice were treated with Ad-Flt3L and Ad-TK 17 days later, whilst PC61 or isotype control immunoglobulins were administered to groups on day 15 or day 24 (Fig. 6A). Here, TKT is linked to glioblastoma.